Parallel Trade Conference 2018

SMi Group6 - 7 February 2018, London, UK.
SMi Group's Parallel Trade conference returns to London for its 12th year. Over the years, the European Single market has allowed for pharmaceuticals to be imported and exported freely between member states without the permission of the manufacturers. However, with the arrival of Brexit and guidelines to immanently enforce the Falsified Medicines Directive (FMD) by 2019, the market for pharmaceutical parallel trade is changing.

The latest changes to regulation, their implementation and major court cases in intellectual property influencing distribution practices will be discussed and will also be explored the safety of patients in relation to the surge in pharmaceutical E-commerce and ways in which currency fluctuations are likely to disrupt the flow of drugs to certain countries in the EU and beyond.

With huge interest from leaders in the field, the conference organisers have worked closely with an expert panel of speakers to present an agenda that is shaping up to be the best Parallel Trade event. This year's event will continue to lead with its unrivalled panel of experts bringing you the most insightful presentations from our confirmed Industry-leading speakers:

  • Antonio Mendonca Alves, CEO, Md Pharma Sa
  • Christopher Stothers, Partner, Arnold And Porter Kaye Scholer Llp
  • Darragh O'loughlin, Secretary General, Irish Pharmacy Union
  • Eric Noehrenberg, President, Noehrenberg International Policy Consulting
  • Fabrizio Gianfrate, Professor of Health Economics, University of Ferrara
  • Farasat Bokhari, Senior Lecturer in Economics, Uea, University of East Anglia
  • Felipe Florez-Arango, Head of Finance, Europe, Shire
  • Frank Weissenfeldt, Senior Manager, Supplier Relations, Quintilesims
  • Heinz Kobelt, Director European Affairs, European Association of Euro-Pharmaceutical Companies
  • Ian Walker, Chairman, Epilepsy Action
  • Janice Haigh, VP Pricing & Market Access, Parexel
  • John Jolley, Managing Director, Pharmaconsult Global Ltd
  • Mikas Rimantas, Business Development Director, Lexano
  • Werner Berg, Partner, Baker & Mckenzie

Parallel Trade will address short term versus long term concerns of pharmaceutical manufacturers, regulators, parallel traders and patient associations.

The 2018 Parallel Trade conference will cover the important issues of:

  • Maintaining the integrity of the supply chain
  • Addressing recent developments concerning intellectual property and regulatory law
  • Forecasting currency fluctuations across the single market and the affect this might have on drug shortages, prices and patient accessibility
  • Exploring how Brexit will impact pharmaceutical trade and market access in Europe
  • Providing an insight into current anti-trust investigations from industry leaders and the consequences this could have on pharmaceutical parallel trade.

For further information and to register, please visit:
http://www.parallel-trade.com

About SMi Group
The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Sanofi and GSK sign agreements with the Government…

Sanofi and GSK have signed agreements with the Government of Canada for the supply of up to 72 million doses of an adjuvanted COVID-19 vaccine, beginning in 2021. Thom...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Johnson & Johnson initiates pivotal global Pha…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, J...

Scientists trace severe COVID-19 to faulty genes a…

More than 10 percent of young and healthy people who develop severe COVID-19 have misguided antibodies that attack not the virus, but the immune system itself, new resear...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

Johns Hopkins researchers publish COVID-19 'predic…

Using a combination of demographic and clinical data gathered from seven weeks of COVID-19 patient care early in the coronavirus pandemic, Johns Hopkins researchers today...

Web resources bring new insight into COVID-19

Researchers around the world are a step closer to a better understanding of the intricacies of COVID-19 thanks to two new web resources developed by investigators at Bayl...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

COVID-19 Long-Acting AntiBody (LAAB) combination A…

AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside th...

Adequate levels of vitamin D reduces complications…

Hospitalized COVID-19 patients who were vitamin D sufficient, with a blood level of 25-hydroxyvitamin D of at least 30 ng/mL (a measure of vitamin D status), had a signif...

Protective antibodies persist for months in surviv…

People who survive serious COVID-19 infections have long-lasting immune responses against the virus, according to a new study led by researchers at Massachusetts General ...